These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30805648)

  • 1. Bridging the gap in outreach and compliance with mass drug administration for lymphatic filariasis elimination in an endemic district in Kerala, India: an intervention research approach.
    Nandha B; Meenakshy V; Abdul Khader N; Vijayakumar KN; Jambulingam P
    Health Educ Res; 2019 Jun; 34(3):300-309. PubMed ID: 30805648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards elimination of lymphatic filariasis: social mobilization issues and challenges in mass drug administration with anti-filarial drugs in Tamil Nadu, South India.
    Nandha B; Krishnamoorthy K; Jambulingam P
    Health Educ Res; 2013 Aug; 28(4):591-8. PubMed ID: 23503571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving Coverage and Compliance in Mass Drug Administration for the Elimination of LF in Two 'Endgame' Districts in Indonesia Using Micronarrative Surveys.
    Krentel A; Damayanti R; Titaley CR; Suharno N; Bradley M; Lynam T
    PLoS Negl Trop Dis; 2016 Nov; 10(11):e0005027. PubMed ID: 27812107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent 'hotspots' of lymphatic filariasis microfilaraemia despite 14 years of mass drug administration in Ghana.
    Biritwum NK; Yikpotey P; Marfo BK; Odoom S; Mensah EO; Asiedu O; Alomatu B; Hervie ET; Yeboah A; Ade S; Hinderaker SG; Reid A; Takarinda KC; Koudou B; Koroma JB
    Trans R Soc Trop Med Hyg; 2016 Dec; 110(12):690-695. PubMed ID: 28938053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphatic filariasis elimination status: Wuchereria bancrofti infections in human populations and factors contributing to continued transmission after seven rounds of mass drug administration in Masasi District, Tanzania.
    Lupenza ET; Gasarasi DB; Minzi OM
    PLoS One; 2022; 17(1):e0262693. PubMed ID: 35045109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards elimination of lymphatic filariasis in southeastern Madagascar: Successes and challenges for interrupting transmission.
    Garchitorena A; Raza-Fanomezanjanahary EM; Mioramalala SA; Chesnais CB; Ratsimbasoa CA; Ramarosata H; Bonds MH; Rabenantoandro H
    PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006780. PubMed ID: 30222758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of mass drug administration on elimination of lymphatic filariasis in Surat city, India.
    Vaishnav KG; Desai HS; Srivastava PK; Joshi PT; Kurian G; Thakor HG; Dhariwal AC
    J Commun Dis; 2012 Dec; 44(4):251-9. PubMed ID: 25145075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coverage and compliance of mass drug administration (MDA) programme for elimination of lymphatic filariasis in an endemic district of eastern Uttar Pradesh, India.
    Bashar A; Nandekar SV; Shrivastava P; Singh RN; Srikrishnan P
    J Vector Borne Dis; 2023; 60(3):307-316. PubMed ID: 37843242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diethylcarbamazine citrate-fortified salt for lymphatic filariasis elimination in India.
    Sabesan S; Krishnamoorthy K; Hoti SL; Subramanian S; Srividya A; Roy N; Jain T; Kumar A; Rahi M
    Indian J Med Res; 2022 Mar; 155(3&4):347-355. PubMed ID: 36124509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mathematical modelling of lymphatic filariasis elimination programmes in India: required duration of mass drug administration and post-treatment level of infection indicators.
    Jambulingam P; Subramanian S; de Vlas SJ; Vinubala C; Stolk WA
    Parasit Vectors; 2016 Sep; 9(1):501. PubMed ID: 27624157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana.
    Manyeh AK; Ibisomi L; Ramaswamy R; Baiden F; Chirwa T
    PLoS Negl Trop Dis; 2020 Aug; 14(8):e0007009. PubMed ID: 32804967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved assessment of mass drug administration and health district management performance to eliminate lymphatic filariasis.
    Maroto-Camino C; Hernandez-Pastor P; Awaca N; Safari L; Hemingway J; Massangaie M; Whitson D; Jeffery C; Valadez JJ
    PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007337. PubMed ID: 31276494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress towards lymphatic filariasis elimination in Ghana from 2000-2016: Analysis of microfilaria prevalence data from 430 communities.
    Biritwum NK; Frempong KK; Verver S; Odoom S; Alomatu B; Asiedu O; Kontoroupis P; Yeboah A; Hervie ET; Marfo B; Boakye DA; de Vlas SJ; Gyapong JO; Stolk WA
    PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007115. PubMed ID: 31398203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coverage of, and compliance with, mass drug administration under the programme to eliminate lymphatic filariasis in India: a systematic review.
    Babu BV; Babu GR
    Trans R Soc Trop Med Hyg; 2014 Sep; 108(9):538-49. PubMed ID: 24728444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study on the factors affecting the MDA programme in Kerala state.
    Showkath Ali MK; Rajendran R; Regu K; Mohanan MK; Dhariwal AC; Lal S
    J Commun Dis; 2007 Mar; 39(1):51-6. PubMed ID: 18338717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential factors influencing lymphatic filariasis transmission in "hotspot" and "control" areas in Ghana: the importance of vectors.
    Pi-Bansa S; Osei JHN; Frempong KK; Elhassan E; Akuoko OK; Agyemang D; Ahorlu C; Appawu MA; Koudou BG; Wilson MD; de Souza DK; Dadzie SK; Utzinger J; Boakye DA
    Infect Dis Poverty; 2019 Feb; 8(1):9. PubMed ID: 30717788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of six rounds of single-dose mass administration of diethylcarbamazine or ivermectin on the transmission of Wuchereria bancrofti by Culex quinquefasciatus and its implications for lymphatic filariasis elimination programmes.
    Ramaiah KD; Das PK; Vanamail P; Pani SP
    Trop Med Int Health; 2003 Dec; 8(12):1082-92. PubMed ID: 14641843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphatic filariasis elimination programme in Andaman and Nicobar Islands, India: drug coverage and compliance post eight rounds of MDA.
    Sunish IP; Shriram AN; Sivan A; Kartick C; Saha BP; Vijayachari P
    Trop Doct; 2013 Jan; 43(1):30-2. PubMed ID: 23550201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing the Antigen Prevalence Target Threshold for Stopping and Restarting Mass Drug Administration for Lymphatic Filariasis Elimination: A Model-Based Cost-effectiveness Simulation in Tanzania, India and Haiti.
    Antony Oliver MC; Graham M; Gass KM; Medley GF; Clark J; Davis EL; Reimer LJ; King JD; Pouwels KB; Hollingsworth TD
    Clin Infect Dis; 2024 Apr; 78(Supplement_2):S160-S168. PubMed ID: 38662697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knowledge on lymphatic filariasis and mass drug administration (MDA) programme in filaria endemic districts of Andhra Pradesh, India.
    Mukhopadhyay AK; Patnaik SK; Satya Babu P; Rao KN
    J Vector Borne Dis; 2008 Mar; 45(1):73-5. PubMed ID: 18399322
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.